AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9256141 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (32 mg I.V. or 8 mg orally twice daily)
Number of subjects: 696
Study 9256141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to dolasetron
Number of subjects: 696
Study 9256141 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to ondansetron
Number of subjects: 696
Study 9256141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone added to both dolasetron and ondansetron
Number of subjects: 696
Study 9256141 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron and ondansetron
Number of subjects: 696
Study 8289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition support via percutaneous endoscopic gastrostomy with a casein and soy-based polymeric formula blended with a modular protein (group A)
Number of subjects: 48
Study 8289411 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition through a subclavian venous catheter (group B)
Number of subjects: 48
Study 2941052 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane (high dose cyproterone acetate with ethinyloestradiol)
Number of subjects: 90
Study 2941052 — intervention group
Group type: COMPARATOR
Intervention: Minovlar (standard oestrogen and progestagen contraceptive pills)
Number of subjects: 90
Study 2941052 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CPA
Number of subjects: 90
Study 31629643 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 28943018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipomimetic drop (Systane® Balance)
Number of subjects: 30
Study 28943018 — intervention group
Group type: COMPARATOR
Intervention: Non‐lipid containing drop (Systane® Ultra)
Number of subjects: 30
Study 27358493 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of controlled cycling and walking training at 80% individual Vo2 peak
Number of subjects: 20
Study 27358493 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β1 as inhibitor of mitochondrial regulators and insulin signaling
Number of subjects: 20
Study 24934642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent dietary intervention
Number of subjects: 0
Study 22313192 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral intervention supplemented with video coaching
Number of subjects: 45
Study 20534872 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative health coaching
Number of subjects: 56
Study 20534872 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly docetaxel
Number of subjects: 1006
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly docetaxel
Number of subjects: 1006
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Number of subjects: 1006
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA response
Number of subjects: 1006
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: pain response
Number of subjects: 1006
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL response
Number of subjects: 1006
Study 18451243 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial increase in serum PSA
Number of subjects: 1006
Study 16416385 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin alone
Number of subjects: 45
Study 16416385 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-retinol combination
Number of subjects: 45
Study 12574177 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 3684
Study 12574177 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/d
Number of subjects: 3684
Study 12574177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3684
Study 10651544 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal band ligation (EVL)
Number of subjects: 40
Study 10651544 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 40
Study 10651544 — intervention group
Group type: COMPARATOR
Intervention: Upper gastrointestinal endoscopy (Control)
Number of subjects: 40
Study 10651544 — intervention group
Group type: COMPARATOR
Intervention: Emergency sclerotherapy (EVS)
Number of subjects: 40
Study 8912123 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily; n = 20)
Number of subjects: 38
Study 8912123 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily; n = 18)
Number of subjects: 38
Study 1747049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 134
Study 1747049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 6181951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 31
Study 6181951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose RSB analgesia
Number of subjects: 56
Study 30842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56
Study 30842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 56
Study 30842172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RSB analgesia)
Number of subjects: 56
Study 30842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 56
Study 30842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign disease patients
Number of subjects: 56
Study 28112814 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct-to-mucosa pancreaticogastrostomy
Number of subjects: 80
Study 28112814 — intervention group
Group type: COMPARATOR
Intervention: Handsewn closure
Number of subjects: 80
Study 26416147 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG vaccine
Number of subjects: 2343
Study 26416147 — intervention group
Group type: COMPARATOR
Intervention: Late BCG (current practice)
Number of subjects: 2343
Study 24628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) after 2 weeks of open-label treatment
Number of subjects: 405
Study 24628498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 24628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) titrated at Weeks 4 or 6
Number of subjects: 405
Study 24628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg for 12 weeks)
Number of subjects: 405
Study 24628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (remission by Week 6 or 8)
Number of subjects: 405
Study 24628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (baseline MADRS below median)
Number of subjects: 405
Study 21767239 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART therapy for 6 months
Number of subjects: 33
Study 21767239 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART therapy for 12 months
Number of subjects: 33
Study 21767239 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 19649993 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cell (BMC) transplantation, intracoronary injection mean 7 days after STEMI
Number of subjects: 60
Study 19649993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMC transplantation)
Number of subjects: 60
Study 17454725 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational information (n=79)
Number of subjects: 157
Study 17454725 — intervention group
Group type: COMPARATOR
Intervention: No educational information (n=78)
Number of subjects: 157
Study 15181616 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-transglutaminase (t-TG) stick
Number of subjects: 142
Study 15181616 — intervention group
Group type: EXPERIMENTAL
Intervention: t-TG/antigliadin antibodies (AGA) stick
Number of subjects: 142
Study 15181616 — intervention group
Group type: COMPARATOR
Intervention: ELISAs
Number of subjects: 142
Study 12520747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin single drug (100 mg/m2, i.v., every 3 weeks)
Number of subjects: 138
Study 12520747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin + vindesine
Number of subjects: 138
Study 12520747 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin + vindesine
Number of subjects: 138
Study 12520747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Number of subjects: 138
Study 9579495 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg bolus, followed by 125 microg/ml via PCA)
Number of subjects: 47
Study 9579495 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (100 microg bolus, followed by 25 microg/ml via PCA)
Number of subjects: 47
Study 7657965 — intervention group
Group type: EXPERIMENTAL
Intervention: Attapulgite (600 mg tablets)
Number of subjects: 30
Study 7657965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2575766 — intervention group
Group type: EXPERIMENTAL
Intervention: suriclone (1.50‐2.25 mg/d)
Number of subjects: 64
Study 2575766 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (5.0‐7.5 mg/d)
Number of subjects: 64
Study 2575766 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 865585 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional sunburn‐spectrum light in gradually increasing doses
Number of subjects: 18
Study 865585 — intervention group
Group type: COMPARATOR
Intervention: Long‐wave ultraviolet light (control group)
Number of subjects: 18
Study 30043678 — intervention group
Group type: COMPARATOR
Intervention: Unloaded walking
Number of subjects: 39
Study 30043678 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing the combat uniform
Number of subjects: 39
Study 30043678 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying the combat uniform plus combat backpack
Number of subjects: 39
Study 28472802 — intervention group
Group type: EXPERIMENTAL
Intervention: LCCP group (n = 50)
Number of subjects: 100
Study 28472802 — intervention group
Group type: COMPARATOR
Intervention: CG1 (n = 33)
Number of subjects: 100
Study 28472802 — intervention group
Group type: COMPARATOR
Intervention: CG2 (n = 17)
Number of subjects: 100
Study 26065565 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitor (celecoxib)
Number of subjects: 12
Study 26065565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (indomethacin)
Number of subjects: 12
Study 26065565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22251427 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Visits (HV)
Number of subjects: 325
Study 22251427 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Contacts (TC)
Number of subjects: 325
Study 22251427 — intervention group
Group type: COMPARATOR
Intervention: Reference Controls (RC)
Number of subjects: 325
Study 21872857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (10 mg/kg)
Number of subjects: 100
Study 21872857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18269305 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n = 279)
Number of subjects: 551
Study 18269305 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (n = 272)
Number of subjects: 551
Study 16530338 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 5x5 Gy radiation with immediate surgery
Number of subjects: 316
Study 16530338 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy, 1.8 Gy per fraction plus boluses of 5‐fluorouracil and leucovorin) with delayed surgery
Number of subjects: 316
Study 16530338 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 316
Study 16530338 — intervention group
Group type: COMPARATOR
Intervention: Short‐course radiation
Number of subjects: 316
Study 12859301 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 46
Study 12859301 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 46
Study 11022267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush Immunotherapy (RIT)
Number of subjects: 18
Study 11022267 — intervention group
Group type: COMPARATOR
Intervention: Conventional Immunotherapy (CIT)
Number of subjects: 18
Study 9206085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at points Neiguan (PC6) and Zusanli (ST36)
Number of subjects: 48
Study 9206085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at non‐acupoints
Number of subjects: 48
Study 9206085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 48
Study 1350686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.05 mg/kg)
Number of subjects: 18
Study 1350686 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.25 mg/kg)
Number of subjects: 18
Study 6548499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepromatous patients
Number of subjects: 360
Study 6548499 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐lepromatous patients
Number of subjects: 360
Study 6548499 — intervention group
Group type: COMPARATOR
Intervention: Control Group (disease-free normal people)
Number of subjects: 360
Study 31964450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelleted diets
Number of subjects: 1152
Study 31964450 — intervention group
Group type: COMPARATOR
Intervention: Mash diets
Number of subjects: 1152
Study 31964450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelleted diets with increasing ME levels
Number of subjects: 1152
Study 31964450 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing ME levels
Number of subjects: 1152
Study 31964450 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing inert material inclusion in diets
Number of subjects: 1152
Study 31810342 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Nutrition Education (IE)
Number of subjects: 170
Study 31810342 — intervention group
Group type: COMPARATOR
Intervention: Group Education (GE)
Number of subjects: 170
Study 30048574 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-/PR- tumors (n=118)
Number of subjects: 693
Study 30048574 — intervention group
Group type: COMPARATOR
Intervention: ER+/PR- subtype (n=77)
Number of subjects: 693
Study 30048574 — intervention group
Group type: COMPARATOR
Intervention: No endocrine therapy for ER+ DCIS
Number of subjects: 693
Study 30048574 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 693
Study 27555146 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil anesthesia
Number of subjects: 60
Study 27555146 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil anesthesia
Number of subjects: 60
Study 27555146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (remifentanil and sufentanil)
Number of subjects: 60
Study 25439407 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.6 mg/kg + Ketamine 0.8 mg/kg + Midazolam 0.06 mg/kg (three-drug group)
Number of subjects: 60
Study 25439407 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg (single-drug group)
Number of subjects: 60
Study 22299761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral branch neurotomy using cooled radiofrequency
Number of subjects: 51
Study 22299761 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 51
Study 19176733 — intervention group
Group type: EXPERIMENTAL
Intervention: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with adequate protein (AP) diet (50-60 g protein/d)
Number of subjects: 80
Study 19176733 — intervention group
Group type: EXPERIMENTAL
Intervention: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with high-protein (HP) diet (100-120 g protein/d)
Number of subjects: 80
Study 19176733 — intervention group
Group type: COMPARATOR
Intervention: adequate protein (AP) diet (50-60 g protein/d) + placebo
Number of subjects: 80
Study 17762661 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic repolarization measures (QT intervals, TPE intervals, T-wave morphology parameters)
Number of subjects: 220
Study 17762661 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographically determined LVM
Number of subjects: 220
Study 15506577 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic communication within a practice-based research network (PBRN)
Number of subjects: 55
Study 15506577 — intervention group
Group type: COMPARATOR
Intervention: Mailed survey instruments to a nationwide sample of family physicians
Number of subjects: 55
Study 11207837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory training of strength, functional performance, and balance 3 times per week for 3 months
Number of subjects: 57
Study 11207837 — intervention group
Group type: COMPARATOR
Intervention: Placebo group attending 3 times a week for 3 months
Number of subjects: 57
Study 11207837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received identical physiotherapeutic treatment 2 times a week, excluding strengthening and balance training
Number of subjects: 57
Study 11207837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 57
Study 9920444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% of total caloric intake as fat)
Number of subjects: 115
Study 9920444 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 115
Study 7999459 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-replacement therapy (ERT) with Premarin at 0.625 mg, days 1-25
Number of subjects: 0
Study 7999459 — intervention group
Group type: COMPARATOR
Intervention: No intervention (study control)
Number of subjects: 0
Study 3258994 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Group (n = 10)
Number of subjects: 20
Study 3258994 — intervention group
Group type: COMPARATOR
Intervention: Voluntary Exercise Group (n = 10)
Number of subjects: 20
Study 29249584 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (300-600 mg/d UFT with 75 mg/d LV on days 1-28, every 35 days, for 5 cycles)
Number of subjects: 966
Study 29249584 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX (100 mg/m2 of oxaliplatin on day 1 with 80-120 mg/d S-1 on days 1-14, every 21 days, for 8 cycles)
Number of subjects: 966
Study 29249584 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX
Number of subjects: 966
Study 29249584 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV
Number of subjects: 966
Study 28797414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low transaortic flow rate (FR) defined as <200 ml/s
Number of subjects: 1661
Study 25632079 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS over right M1 (n = 10)
Number of subjects: 28
Study 25632079 — intervention group
Group type: COMPARATOR
Intervention: s-tDCS (n = 10)
Number of subjects: 28
Study 25632079 — intervention group
Group type: COMPARATOR
Intervention: a-tDCS over right M1 without MVF (n = 8)
Number of subjects: 28
Study 23921143 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 36
Study 23921143 — intervention group
Group type: COMPARATOR
Intervention: Erythropoiesis-stimulating agent (ESA)
Number of subjects: 36
Study 23921143 — intervention group
Group type: EXPERIMENTAL
Intervention: ESA and endurance training
Number of subjects: 36
Study 23921143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21385195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 4.8 g/day
Number of subjects: 0
Study 21385195 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 2.4 g/day
Number of subjects: 0
Study 17853395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (target dose, 2700 mg) for 6 weeks
Number of subjects: 115
Study 17853395 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 115
Study 15460358 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-min. guided imagery
Number of subjects: 42
Study 15460358 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study 11603905 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9696975 — intervention group
Group type: EXPERIMENTAL
Intervention: One litre water and glycerine enema the day before operation (n = 53)
Number of subjects: 106
Study 9696975 — intervention group
Group type: COMPARATOR
Intervention: No preoperative intestinal preparation (n = 53)
Number of subjects: 106
Study 8014550 — intervention group
Group type: EXPERIMENTAL
Intervention: A1 pulley divided
Number of subjects: 100
Study 8014550 — intervention group
Group type: COMPARATOR
Intervention: A1 pulley retained
Number of subjects: 100
Study 2612087 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine plus ethanol
Number of subjects: 10
Study 2612087 — intervention group
Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 10
Study 1095964 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (150 mg daily) and vitamin B-12 (2000 gamma)
Number of subjects: 53
Study 1095964 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B-12 (2000 gamma) alone
Number of subjects: 53
Study 31838011 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 710
Study 31838011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 29730393 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality games (VIGOR) played for nine weeks
Number of subjects: 0
Study 29730393 — intervention group
Group type: COMPARATOR
Intervention: Traditional graded activity or graded exposure therapies
Number of subjects: 0
Study 27714429 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg LSD
Number of subjects: 40
Study 27714429 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 40
Study 27714429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26279073 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg chromium picolinate supplements
Number of subjects: 64